Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling

被引：14

作者：

Dowdy, D. W. ^{[1
]}

Houben, R. ^{[2
]}

Cohen, T. ^{[3
]}

Pai, M. ^{[4
,5
]}

Cobelens, F. ^{[6
,7
]}

Vassall, A. ^{[8
]}

Menzies, N. A. ^{[9
]}

Gomez, G. B. ^{[6
,7
]}

Langley, I. ^{[10
,11
]}

Squire, S. B. ^{[10
,11
]}

White, R. ^{[2
]}

机构：

[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA

[2] Univ London London Sch Hyg & Trop Med, Epidemiol & TB Modelling Grp, Dept Infect Dis, London WC1E 7HT, England

[3] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA

[4] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada

[5] McGill Univ, McGill Int TB Ctr, Montreal, PQ, Canada

[6] Univ Amsterdam, Acad Med Ctr, Dept Global Hlth, NL-1105 AZ Amsterdam, Netherlands

[7] Univ Amsterdam, Acad Med Ctr, Amsterdam Inst Global Hlth & Dev, NL-1105 AZ Amsterdam, Netherlands

[8] Univ London London Sch Hyg & Trop Med, Dept Global Hlth & Dev, SAME Modelling & Econ, London WC1E 7HT, England

[9] Harvard Univ, Sch Publ Hlth, Ctr Hlth Decis Sci, Boston, MA 02115 USA

[10] Univ Liverpool, Liverpool Sch Trop Med, Dept Clin Sci, Liverpool L3 5QA, Merseyside, England

[11] Univ Liverpool, Liverpool Sch Trop Med, Ctr Appl Hlth Res & Delivery, Liverpool L3 5QA, Merseyside, England

来源：

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE | 2014年 / 18卷 / 09期

关键词：

tuberculosis; modelling; diagnostics; POINT-OF-CARE; XPERT MTB/RIF; AFRICA; BURDEN; TESTS; PYRAZINAMIDE; FRAMEWORK; DISEASE; DRUGS;

D O I：

10.5588/ijtld.13.0851

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The landscape of diagnostic testing for tuberculosis (TB) is changing rapidly, and stakeholders need urgent guidance on how to develop, deploy and optimize TB diagnostics in a way that maximizes impact and makes best use of available resources. When decisions must be made with only incomplete or preliminary data available, modelling is a useful tool for providing such guidance. Following a meeting of modelers and other key stakeholders organized by the TB Modelling and Analysis Consortium, we propose a conceptual framework for positioning models of TB diagnostics. We use that framework to describe modelling priorities in four key areas: Xpert (R) MTB/RIF scale-up, target product profiles for novel assays, drug susceptibility testing to support new drug regimens, and the improvement of future TB diagnostic models. If we are to maximize the impact and cost-effectiveness of TB diagnostics, these modelling priorities should figure prominently as targets for future research.

引用

页码：1012 / 1018

页数：7

共 35 条

[1] Challenges in Evaluating the Cost-effectiveness of New Diagnostic Tests for HIV-Associated Tuberculosis [J].

Andrews, Jason R. ;

Lawn, Stephen D. ;

Dowdy, David W. ;

Walensky, Rochelle P. .

CLINICAL INFECTIOUS DISEASES, 2013, 57 (07) :1021-1026

[2] The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis [J].

Andrews, Jason R. ;

Lawn, Stephen D. ;

Rusu, Corina ;

Wood, Robin ;

Noubary, Farzad ;

Bender, Melissa A. ;

Horsburgh, C. Robert ;

Losina, Elena ;

Freedberg, Kenneth A. ;

Walensky, Rochelle P. .

AIDS, 2012, 26 (08) :987-995

[3]

[Anonymous], EUR RESP J

[4] Tuberculosis and poverty: the contribution of patient costs in sub-Saharan Africa - a systematic review [J].

Barter, Devra M. ;

Agboola, Stephen O. ;

Murray, Megan B. ;

Baernighausen, Till .

BMC PUBLIC HEALTH, 2012, 12

[5] Pyrazinamide Susceptibility Testing in Mycobacterium tuberculosis: a Systematic Review with Meta-Analyses [J].

Chang, Kwok Chiu ;

Yew, Wing Wai ;

Zhang, Ying .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (10) :4499-4505

[6]

Cohen Ted, 2009, Expert Rev Respir Med, V3, P67, DOI 10.1586/17476348.3.1.67

[7] 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial [J].

Diacon, Andreas H. ;

Dawson, Rodney ;

von Groote-Bidlingmaier, Florian ;

Symons, Gregory ;

Venter, Amour ;

Donald, Peter R. ;

van Niekerk, Christo ;

Everitt, Daniel ;

Winter, Helen ;

Becker, Piet ;

Mendel, Carl M. ;

Spigelman, Melvin K. .

LANCET, 2012, 380 (9846) :986-993

[8]

Dowdy DW, 2008, INT J TUBERC LUNG D, V12, P1021

[9] Data needs for evidence-based decisions: a tuberculosis modeler's 'wish list' [J].

Dowdy, D. W. ;

Dye, C. ;

Cohen, T. .

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2013, 17 (07) :866-877

[10] Is Passive Diagnosis Enough? The Impact of Subclinical Disease on Diagnostic Strategies for Tuberculosis [J].

Dowdy, David W. ;

Basu, Sanjay ;

Andrews, Jason R. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187 (05) :543-551

← 1 2 3 4 →